Table 1 (abstract O14). Most frequent events of special interest ordered by decreasing frequencies. Data are absolute numbers and frequencies (%)
From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Pharmachild N = 2,022 (%) | BiKeR N=1,697 (%) | |
|---|---|---|
Infections: | 1523 (75.3) | 1509 (89) |
Serious/targeted infections (Epstein‐Barr virus, cytomegalovirus, papilloma virus, herpes zoster primary and reactivation, and opportunistic infections) | 674 (33.3) | 171 (10.1) |
Tuberculosis | 27 (1,3) | 0 |
Other infections | 822 (40.6) | 1338 (78.8) |
Infusion/injection related reactions: | 218 (10.8) | 24 (1.4) |
Infusion related reaction | 144 (7.1) | 11 (0.6) |
Injection related reaction | 74 (3.7) | 13 (0.8) |
Blood cells related ESI: | 188 (9.3) | 90 (5.3) |
Pancytopenia | 6 (0.3) | 65 (3.8) |
Neutropenia | 107 (5.3) | 14 (0.8) |
Macrophage activation syndrome | 75 (3.7) | 11 (0.6) |
Aplastic anemia | 0 | 0 |
Autoimmune ESI: | 50 (2.5) | 50 (2.9) |
Inflammatory Bowel Disease (IBD) | 21 (1.1) | 23 (1.3) |
Other autoimmune diseases excluding IBD, uveitis and demyelinisation disorders | 18 (0.9) | 24 (1.4) |
Lupus erythematosus systemic/lupus-like syndrome | 4 (0.2) | 1 (0.1) |
Optic neuritis | 4 (0.2) | 0 |
Multiple sclerosis | 2 (0.1) | 0 |
Demyelination | 1 (0.05) | 2 (0.2) |
Malignancies: | 16 (0.8) | 13 (0.8) |
Leukaemias | 3 (0.1) | 2 (0.2) |
Lymphomas | 2 (0.1) | 5 (0.3) |
Haematopoietic neoplasms (excluding leukaemias and lymphomas) | 1 (0.05) | 2 (0.2) |
Neoplasm (other) | 10 (0.5) | 4 (0.2) |